170 related articles for article (PubMed ID: 25078132)
21. Going over the patent cliff.
Schommer JC
Minn Med; 2011 Oct; 94(10):42-3. PubMed ID: 23256283
[No Abstract] [Full Text] [Related]
22. Pharmaceutical policy in Italy: towards a structural change?
Ghislandi S; Krulichova I; Garattini L
Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
[TBL] [Abstract][Full Text] [Related]
23. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
Graul AI; Revel L; Rosa E; Cruces E
Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
[TBL] [Abstract][Full Text] [Related]
24. IP litigation in China could drive innovation.
Jia H
Nat Biotechnol; 2004 Apr; 22(4):368. PubMed ID: 15060539
[No Abstract] [Full Text] [Related]
25. A generic problem.
Hanauer SB
Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
[No Abstract] [Full Text] [Related]
26. 13th EGA annual conference. Challenges in the European and global environment for the generic medicines industry.
Kuhrt K
IDrugs; 2007 Aug; 10(8):549-53. PubMed ID: 17665329
[No Abstract] [Full Text] [Related]
27. The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?
Sarpatwari A; Kesselheim AS
PLoS Med; 2016 Feb; 13(2):e1001955. PubMed ID: 26859662
[TBL] [Abstract][Full Text] [Related]
28. India: access to affordable drugs and the right to health.
Grover A; Citro B
Lancet; 2011 Mar; 377(9770):976-7. PubMed ID: 21227487
[No Abstract] [Full Text] [Related]
29. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
Higgins MJ; Graham SJ
Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
[No Abstract] [Full Text] [Related]
30. Watch for these new generics.
Consum Rep; 2012 May; 77(5):12. PubMed ID: 22641866
[No Abstract] [Full Text] [Related]
31. Prescription drug pushers. Patents and ads are the big reasons pills are priced like perfume and caviar.
Sherrid P
US News World Rep; 2000 Oct; 129(17):40-2. PubMed ID: 11184929
[No Abstract] [Full Text] [Related]
32. Patent cliff mitigation strategies: giving new life to blockbusters.
Kakkar AK
Expert Opin Ther Pat; 2015; 25(12):1353-9. PubMed ID: 26372691
[TBL] [Abstract][Full Text] [Related]
33. [Patients, patents and profits].
Roland PC
Tidsskr Nor Laegeforen; 2008 Jan; 128(2):205. PubMed ID: 18202741
[No Abstract] [Full Text] [Related]
34. Don't pay too much for generic fills. Pass-through pricing is a good way for a payer to realize the benefit of increased prescribing of generic drugs.
Cahn LJ
Manag Care; 2010 Nov; 19(11):21-7. PubMed ID: 21141372
[No Abstract] [Full Text] [Related]
35. Competition and the Reference Pricing Scheme for pharmaceuticals.
Ghislandi S
J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
[TBL] [Abstract][Full Text] [Related]
36. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.
Panattoni LE
J Health Econ; 2011 Jan; 30(1):126-45. PubMed ID: 21074873
[TBL] [Abstract][Full Text] [Related]
37. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
Wang Z
Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
[No Abstract] [Full Text] [Related]
38. Generics battle brand names over mortality of drug patents.
Betz R
J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
[No Abstract] [Full Text] [Related]
39. [The patent is "engine" in drug development].
Bergström R
Lakartidningen; 2008 Mar 5-11; 105(10):752. PubMed ID: 18422246
[No Abstract] [Full Text] [Related]
40. Delaying generic competition--corporate payoffs and the future of Plavix.
Shuchman M
N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
